Cargando…

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma

BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayikcioglu, Erkan, Yüceer, Ramazan Oğuz, Cetin, Bulent, Yüceer, Kamuran, Karahan, Nermin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994048/
https://www.ncbi.nlm.nih.gov/pubmed/36908327
http://dx.doi.org/10.4251/wjgo.v15.i2.343
_version_ 1784902600541339648
author Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
Cetin, Bulent
Yüceer, Kamuran
Karahan, Nermin
author_facet Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
Cetin, Bulent
Yüceer, Kamuran
Karahan, Nermin
author_sort Kayikcioglu, Erkan
collection PubMed
description BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenocarcinoma. AIM: To identify the prognostic value of CLDN18.2 expression in patients with metastatic gastric adenocarcinoma. METHODS: This study was conducted with 65 patients over the age of 18 who were diagnosed with metastatic gastric adenocarcinoma. We investigated the effect of CLDN18.2 expression on clinicopathological characteristics (age, sex, histological grade, Lauren classification, family history, metastatic site, HER2 expression) and prognosis for patients with metastatic gastric adenocarcinoma. RESULTS: CLDN18.2 expression was positive in 73.8% (48) of the patients. During the median 17.7-mo follow-up period, 89.2% (58) of the patients died. Median progression-free survival and overall survival (OS) were 6 mo (95% confidence interval: 1.6-10.4) and 12 mo (95% confidence interval: 7.5-16.5). There was no statistically significant correlation between CLDN18.2 expression and clinicopathological characteristics of the patients. In univariate and multivariate Cox regression analysis, there was no correlation between clinicopathological characteristics of patients and progression-free survival or OS. CONCLUSION: CLDN18.2 expression was quite high in patients with gastric adenocarcinoma, identifying the proportion of the patients in whom zolbetuximab would be efficacious. There is no statistically significant correlation with clinicopathological characteristics and OS. CLDN18.2 is not a prognostic marker in patients with gastric adenocarcinoma, although it is predictive.
format Online
Article
Text
id pubmed-9994048
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-99940482023-03-09 Prognostic value of claudin 18.2 expression in gastric adenocarcinoma Kayikcioglu, Erkan Yüceer, Ramazan Oğuz Cetin, Bulent Yüceer, Kamuran Karahan, Nermin World J Gastrointest Oncol Retrospective Cohort Study BACKGROUND: Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenocarcinoma. AIM: To identify the prognostic value of CLDN18.2 expression in patients with metastatic gastric adenocarcinoma. METHODS: This study was conducted with 65 patients over the age of 18 who were diagnosed with metastatic gastric adenocarcinoma. We investigated the effect of CLDN18.2 expression on clinicopathological characteristics (age, sex, histological grade, Lauren classification, family history, metastatic site, HER2 expression) and prognosis for patients with metastatic gastric adenocarcinoma. RESULTS: CLDN18.2 expression was positive in 73.8% (48) of the patients. During the median 17.7-mo follow-up period, 89.2% (58) of the patients died. Median progression-free survival and overall survival (OS) were 6 mo (95% confidence interval: 1.6-10.4) and 12 mo (95% confidence interval: 7.5-16.5). There was no statistically significant correlation between CLDN18.2 expression and clinicopathological characteristics of the patients. In univariate and multivariate Cox regression analysis, there was no correlation between clinicopathological characteristics of patients and progression-free survival or OS. CONCLUSION: CLDN18.2 expression was quite high in patients with gastric adenocarcinoma, identifying the proportion of the patients in whom zolbetuximab would be efficacious. There is no statistically significant correlation with clinicopathological characteristics and OS. CLDN18.2 is not a prognostic marker in patients with gastric adenocarcinoma, although it is predictive. Baishideng Publishing Group Inc 2023-02-15 2023-02-15 /pmc/articles/PMC9994048/ /pubmed/36908327 http://dx.doi.org/10.4251/wjgo.v15.i2.343 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Kayikcioglu, Erkan
Yüceer, Ramazan Oğuz
Cetin, Bulent
Yüceer, Kamuran
Karahan, Nermin
Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title_full Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title_fullStr Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title_full_unstemmed Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title_short Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
title_sort prognostic value of claudin 18.2 expression in gastric adenocarcinoma
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994048/
https://www.ncbi.nlm.nih.gov/pubmed/36908327
http://dx.doi.org/10.4251/wjgo.v15.i2.343
work_keys_str_mv AT kayikciogluerkan prognosticvalueofclaudin182expressioningastricadenocarcinoma
AT yuceerramazanoguz prognosticvalueofclaudin182expressioningastricadenocarcinoma
AT cetinbulent prognosticvalueofclaudin182expressioningastricadenocarcinoma
AT yuceerkamuran prognosticvalueofclaudin182expressioningastricadenocarcinoma
AT karahannermin prognosticvalueofclaudin182expressioningastricadenocarcinoma